MCID: CNT018
MIFTS: 35

Central Nervous System Leukemia

Categories: Blood diseases, Cancer diseases, Neuronal diseases

Aliases & Classifications for Central Nervous System Leukemia

MalaCards integrated aliases for Central Nervous System Leukemia:

Name: Central Nervous System Leukemia 12 15 71
Leukemia of the Cns 12

Classifications:



External Ids:

Disease Ontology 12 DOID:12969
NCIt 49 C5440
UMLS 71 C1332884

Summaries for Central Nervous System Leukemia

Disease Ontology : 12 A hematologic cancer located in the central nervous system.

MalaCards based summary : Central Nervous System Leukemia, also known as leukemia of the cns, is related to leukemia, acute monocytic and acute leukemia. An important gene associated with Central Nervous System Leukemia is LIF (LIF Interleukin 6 Family Cytokine), and among its related pathways/superpathways are Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell and Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers. The drugs Methotrexate and leucovorin have been mentioned in the context of this disorder. Affiliated tissues include central nervous system, myeloid and breast, and related phenotype is integument.

Related Diseases for Central Nervous System Leukemia

Diseases related to Central Nervous System Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 109)
# Related Disease Score Top Affiliating Genes
1 leukemia, acute monocytic 29.7 CD33 ANPEP
2 acute leukemia 29.3 CD7 CD34 CD33 ANPEP
3 combined t cell and b cell immunodeficiency 29.3 CD34 CD19
4 leukemia, chronic myeloid 29.2 CD34 CD33 CD19 ANPEP
5 leukemia, acute lymphoblastic 3 29.1 MME CD34 CD19 ANPEP
6 precursor t-cell acute lymphoblastic leukemia 28.9 CD7 CD34 CD33 ANPEP
7 lymphoma, non-hodgkin, familial 28.5 MME CD7 CD34 CD19 CARTPT
8 hematologic cancer 28.4 MME CD7 CD34 CD33 CD19
9 acute promyelocytic leukemia 28.3 CD7 CD34 CD33 ANPEP
10 pancytopenia 28.1 CD7 CD34 CD33 CD19 ANPEP
11 leukemia, acute lymphoblastic 27.8 MME CD7 CD34 CD33 CD19 CARTPT
12 leukemia, acute myeloid 26.9 MME CD7 CD34 CD33 CD19 CARTPT
13 leukemia 10.7
14 lymphocytic leukemia 10.6
15 invasive malignant thymoma 10.4 MME CD19
16 adult lymphoma 10.3 MME CD19
17 cll/sll 10.3 MME CD19
18 inflammatory bowel disease 16 10.3 LIF CD7
19 plasma protein metabolism disease 10.2 MME CD19
20 myeloid leukemia 10.2
21 cardiomyopathy, dilated, 1c, with or without left ventricular noncompaction 10.2 CD33 CD19
22 refractory hematologic cancer 10.2 CD19 CARTPT
23 plasma cell neoplasm 10.2 MME CD19
24 relapsed/refractory diffuse large b-cell lymphoma 10.2 CD19 CARTPT
25 gastric lymphoma 10.1 MME CD7
26 childhood acute lymphocytic leukemia 10.1
27 childhood leukemia 10.1
28 monocytic leukemia 10.1
29 b-cell adult acute lymphocytic leukemia 10.1 CD19 ANPEP
30 adenomyosis 10.1 MME LIF
31 aleukemic leukemia cutis 10.1 CD33 ANPEP
32 burkitt lymphoma 10.0
33 lymphoma, hodgkin, classic 10.0
34 lymphoma 10.0
35 papilledema 10.0
36 paraplegia 10.0
37 severe combined immunodeficiency 10.0
38 diabetes insipidus 10.0
39 hypereosinophilic syndrome 10.0
40 acute monoblastic leukemia 10.0
41 precursor b lymphoblastic lymphoma/leukemia 10.0 CD7 ANPEP
42 myelophthisic anemia 10.0 CD33 ANPEP
43 breast rhabdomyosarcoma 10.0 CD33 ANPEP
44 otosalpingitis 10.0 CD34 CD19
45 central nervous system hematologic cancer 10.0 MME CD19 CARTPT
46 breast myofibroblastoma 10.0 MME CD34
47 pacinian tumor 10.0 MME CD34
48 breast leiomyoma 10.0 MME CD34
49 inflammatory liposarcoma 9.9 MME CD34
50 sarcomatoid squamous cell skin carcinoma 9.9 MME CD34

Graphical network of the top 20 diseases related to Central Nervous System Leukemia:



Diseases related to Central Nervous System Leukemia

Symptoms & Phenotypes for Central Nervous System Leukemia

MGI Mouse Phenotypes related to Central Nervous System Leukemia:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 integument MP:0010771 9.1 ANPEP ASPG CD19 CD34 LIF MME

Drugs & Therapeutics for Central Nervous System Leukemia

Drugs for Central Nervous System Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 50)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methotrexate Approved Phase 2, Phase 3 1959-05-2, 59-05-2 126941
2
leucovorin Approved Phase 2, Phase 3 58-05-9 6006 143
3
Mercaptopurine Approved Phase 2, Phase 3 50-44-2 667490
4
Vincristine Approved, Investigational Phase 2, Phase 3 2068-78-2, 57-22-7 5978
5
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2, Phase 3 1177-87-3
6
Dexamethasone Approved, Investigational, Vet_approved Phase 2, Phase 3 50-02-2 5743
7
Idarubicin Approved Phase 2, Phase 3 58957-92-9 42890
8
Cyclophosphamide Approved, Investigational Phase 2, Phase 3 50-18-0, 6055-19-2 2907
9
Etoposide Approved Phase 2, Phase 3 33419-42-0 36462
10
Pegaspargase Approved, Investigational Phase 2, Phase 3 130167-69-0
11
Prednisone Approved, Vet_approved Phase 2, Phase 3 53-03-2 5865
12
Cytarabine Approved, Experimental, Investigational Phase 2, Phase 3 147-94-4, 65-46-3 6253
13
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
14
Folic acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 59-30-3 6037
15 Immunologic Factors Phase 2, Phase 3
16 Folic Acid Antagonists Phase 2, Phase 3
17 Vitamin B Complex Phase 2, Phase 3
18 Antimitotic Agents Phase 2, Phase 3
19 Vitamin B9 Phase 2, Phase 3
20 Dermatologic Agents Phase 2, Phase 3
21 Folate Phase 2, Phase 3
22 Antirheumatic Agents Phase 2, Phase 3
23 Immunosuppressive Agents Phase 2, Phase 3
24 Antimetabolites Phase 2, Phase 3
25 Antiemetics Phase 2, Phase 3
26 Gastrointestinal Agents Phase 2, Phase 3
27 HIV Protease Inhibitors Phase 2, Phase 3
28 Alkylating Agents Phase 2, Phase 3
29
protease inhibitors Phase 2, Phase 3
30 Anti-Infective Agents Phase 2, Phase 3
31 Autonomic Agents Phase 2, Phase 3
32 Hormone Antagonists Phase 2, Phase 3
33 Antiviral Agents Phase 2, Phase 3
34 Anti-Inflammatory Agents Phase 2, Phase 3
35 Antineoplastic Agents, Hormonal Phase 2, Phase 3
36 Histone Deacetylase Inhibitors Phase 2, Phase 3
37 BB 1101 Phase 2, Phase 3
38 glucocorticoids Phase 2, Phase 3
39 Etoposide phosphate Phase 2, Phase 3
40 Hormones Phase 2, Phase 3
41 Anti-Bacterial Agents Phase 3
42 Antibiotics, Antitubercular Phase 3
43 Topoisomerase Inhibitors Phase 3
44
Liposomal doxorubicin Phase 3 31703
45
asparaginase Phase 3
46 razoxane Phase 3
47 Protective Agents Phase 3
48 Protein Kinase Inhibitors Phase 2
49 Imatinib Mesylate Phase 2 220127-57-1 123596
50 Cola

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 An Open-Label, One-Arm, Multi-Site Trial of Precision Diagnosis Directing Histone Deacetylase Inhibitor Chidamide Total Therapy for Adult T-lymphoblastic Lymphoma/Leukemia Recruiting NCT03564704 Phase 2, Phase 3 Dexamethasone;vincristine;Cyclophosphamide;Idarubicin;Pegaspargase;Adriamycin;Methotrexate;6-mercaptopurine.;Etoposide;Cytarabine;Chidamide
2 An Open-Label, One-Arm, Multi-Site Trial of Precision Diagnosis Directing Histone Deacetylase Inhibitor Chidamide Target Total Therapy for Adult Early T-cell Progenitor Acute Lymphoblastic Leukemia/Lymphoma Recruiting NCT03553238 Phase 2, Phase 3 Chidamide;Dexamethasone;vincristine;Cyclophosphamide;Idarubicin;Pegaspargase;Adriamycin;Methotrexate;6-Mercaptopurine;Etoposide;Cytarabine
3 Treatment of Childhood Acute Lymphoblastic Leukemia Terminated NCT00165087 Phase 3 asparaginase (E. Coli);asparaginase (Erwina);dexrazoxane;doxorubicin
4 Evaluation of Imatinib (GLIVEC) After Induction Therapy in Patients Aged More Than 55 Years With Philadelphia Positive Acute Lymphoblastic Leukaemia (Ph+ ALL) : a Non Randomised, Controlled, Open, Multicentric, International Phase II Clinical Study (CSTI 571 AFR09 Trial) Unknown status NCT00149136 Phase 2 imatinib
5 Descriptive Study to Evaluate the Information and Psychosocial Issues on the Risk on Infertility in Cancer Patients After Receiving Treatment in a Comprehensive Cancer Center Unknown status NCT01295463
6 Chemotherapy-induced Nausea and Vomiting in Children Receiving Intrathecal Methotrexate With/Without Vincristine Completed NCT01661413

Search NIH Clinical Center for Central Nervous System Leukemia

Genetic Tests for Central Nervous System Leukemia

Anatomical Context for Central Nervous System Leukemia

The Foundational Model of Anatomy Ontology organs/tissues related to Central Nervous System Leukemia:

19
Central Nervous System

MalaCards organs/tissues related to Central Nervous System Leukemia:

40
Myeloid, Breast, T Cells, B Cells, Bone, Bone Marrow, Monocytes

Publications for Central Nervous System Leukemia

Articles related to Central Nervous System Leukemia:

(show top 50) (show all 252)
# Title Authors PMID Year
1
[Clinical Analysis of Dasatinib and Chemotherapy Followed by Allogeneic Hematopoietic Stem Cell Transplantation for Treatment of Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia]. 61
32027247 2020
2
Effect of Dasatinib vs Imatinib in the Treatment of Pediatric Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Randomized Clinical Trial. 61
31944221 2020
3
Ponatinib therapy in recurrent Philadelphia chromosome-positive central nervous system leukemia with T315I mutation after Allo-HSCT. 61
31785158 2019
4
Disrupting the leukemia niche in the central nervous system attenuates leukemia chemoresistance. 61
31624109 2019
5
Glucocorticoids and selumetinib are highly synergistic in RAS pathway-mutated childhood acute lymphoblastic leukemia through upregulation of BIM. 61
30655370 2019
6
Anti-CD19 CAR-T as a feasible and safe treatment against central nervous system leukemia after intrathecal chemotherapy in adults with relapsed or refractory B-ALL. 61
30846865 2019
7
Eradication of Central Nervous System Leukemia of T-Cell Origin with a Brain-Permeable LSD1 Inhibitor. 61
30518632 2019
8
[Detection Rate of Central Nervous System Leukemia Can Be Improved by Cell Preservation Solution]. 61
30738441 2019
9
Altered CSF Proteomic Profiling of Paediatric Acute Lymphocytic Leukemia Patients with CNS Infiltration. 61
31186631 2019
10
Functional Improvement of Chimeric Antigen Receptor Through Intrinsic Interleukin-15Rα Signaling. 61
30444200 2019
11
[Clinical Significance of Additional Chromosomal 8 Clonal Evolution in CML Progression]. 61
30501690 2018
12
Rhabdomyolysis during myelosuppression in a patient with central nervous system leukemia: A case report. 61
30407314 2018
13
Chronic myeloid leukemia extramedullary blast crisis presenting as central nervous system leukemia: A case report. 61
30407337 2018
14
Identifying and Understanding the Gaps in Care Experienced by Adolescent and Young Adult Cancer Patients at the University of Iowa Hospitals and Clinics. 61
29924681 2018
15
Radiation in Central Nervous System Leukemia: Guidelines From the International Lymphoma Radiation Oncology Group. 61
30102203 2018
16
[Analysis of Factors Influencing Prognosis of 87 Adults with Ph Chromosome Negative ALL]. 61
30111399 2018
17
[Treatment of central nervous system leukemia with CD19-chimeric antigen receptor T-cell immunotherapy: two cases report and literature review]. 61
30180466 2018
18
[Analysis of Prognostic Factors for 96 Patients with Acute Lymphoblastic Leukemia]. 61
30111398 2018
19
Haploidentical hematopoietic SCT using helical tomotherapy for total-body irradiation and targeted dose boost in patients with high-risk/refractory acute lymphoblastic leukemia. 61
29330392 2018
20
A retrospective comparison of Escherichia coli and polyethylene glycol-conjugated asparaginase for the treatment of adolescents and adults with newly diagnosed acute lymphoblastic leukemia. 61
29387211 2018
21
Experiment research of focused ultrasound combined with drug and microbubble for treatment of central nervous system leukemia. 61
29435190 2018
22
Central nervous system leukemia in a patient with concurrent nasopharyngeal carcinoma and acute myeloid leukaemia: A case report. 61
29384905 2017
23
[Clinical Analysis of 7 Children with Mature B-cell Acute Lymphoblastic Leukemia]. 61
29070107 2017
24
Outcome and Clinical Significance of Immunophenotypic Markers Expressed in Different Treatment Protocols of Pediatric Patients With T-ALL in Developing Countries. 61
28624542 2017
25
Severe Hyponatremia in a Single-Center Series of 84 Homogenously Treated Children With Acute Lymphoblastic Leukemia. 61
28060134 2017
26
The role of ZAP70 kinase in acute lymphoblastic leukemia infiltration into the central nervous system. 61
27686375 2017
27
[Clinical Characteristics and Prognosis of 21 Cases of Acute Lymphoblastic Leukemia with Central Nervous System Leukemia]. 61
28024476 2016
28
[Critical roles of matrix metalloproteinases secreted by leukemic cells in the pathogenesis of central nervous system leukemia]. 61
28088972 2016
29
[The prognostic significance of proportion of blasts in bone marrow on day 14 during induction chemotherapy in patients with adult Ph-negative acute lymphoblastic leukemia]. 61
27431075 2016
30
Transverse myelopathy occurring with intrathecal administration of methotrexate and cytarabine chemotherapy: A case report. 61
27313742 2016
31
Outcome of Children with Standard-Risk T-Lineage Acute Lymphoblastic Leukemia--Comparison among Different Treatment Strategies. 61
26485054 2016
32
Paving the road ahead for CD19 CAR T-cell therapy. 61
26335422 2015
33
[Leukotriene B4 level in cerebrospinal fluid of patients with tuberculosis meningitis and clinical significance]. 61
26271986 2015
34
Blastic plasmacytoid dendritic cell neoplasm with leukemic manifestation and ETV6 gene rearrangement: A case report. 61
25780395 2015
35
Comprehensive craniospinal radiation for controlling central nervous system leukemia. 61
25539370 2014
36
Advances in treatment of de-novo pediatric acute myeloid leukemia. 61
25226383 2014
37
Superior survival of unmanipulated haploidentical hematopoietic stem cell transplantation compared with chemotherapy alone used as post-remission therapy in adults with standard-risk acute lymphoblastic leukemia in first complete remission. 61
24747334 2014
38
Establishment of NOD/SCID mouse model of central nervous system leukemia. 61
24927394 2014
39
[Research progress on drug-loaded microbubble targeting treatment of central nervous system leukemia]. 61
24989314 2014
40
The emerging and diverse roles of sirtuins in cancer: a clinical perspective. 61
24133372 2013
41
[Analysis of multicenter efficacy of acute lymphoblastic leukemia in older children]. 61
23906450 2013
42
Outcome of childhood acute Lymphoblastic leukemia in Egyptian children: a challenge for limited health resource countries. 61
23394310 2013
43
A practical strategy of monitoring minimal residue disease and intervention for central nervous system relapse of childhood acute lymphoblastic leukemia: a single Chinese center's experience. 61
23787730 2013
44
The soluble VEGF receptor 1 and 2 expression in cerebral spinal fluid as an indicator for leukemia central nervous system metastasis. 61
23400753 2013
45
[Expression of osteopontin in central nervous system leukemia and its clinical significance]. 61
23628025 2013
46
Diagnosis and treatment of a patient with isolated spinal granulocytic sarcoma: A case report. 61
23599768 2013
47
Central nervous system involvement of primary renal lymphoma with diffuse large B-cell type lymphoma. 61
23940823 2013
48
Intracerebral metastasis in pediatric acute lymphoblastic leukemia: A rare presentation. 61
23560011 2012
49
Phase 2 clinical trial of intrathecal topotecan in children with refractory leptomeningeal leukemia: a Children's Oncology Group trial (P9962). 61
21910214 2012
50
[Clinical diagnostic significance of cerebrospinal fluid detection with flow cytometry in children acute lymphoblastic leukemia accompanied by central nervous system leukemia]. 61
22391161 2012

Variations for Central Nervous System Leukemia

Expression for Central Nervous System Leukemia

Search GEO for disease gene expression data for Central Nervous System Leukemia.

Pathways for Central Nervous System Leukemia

GO Terms for Central Nervous System Leukemia

Cellular components related to Central Nervous System Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 8.92 CD34 CD33 CD19 ANPEP

Biological processes related to Central Nervous System Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 regulation of immune response GO:0050776 9.13 CD34 CD33 CD19
2 cell-cell signaling GO:0007267 8.8 CD33 CARTPT AFDN

Molecular functions related to Central Nervous System Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling receptor activity GO:0038023 8.8 CD7 CD33 ANPEP

Sources for Central Nervous System Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....